PERTH, Australia – After reporting positive data at the American Society of Clinical Oncology (ASCO) meeting for its Akt inhibitor in estrogen receptor (ER)-positive breast cancer, Melbourne-based Prescient Therapeutics Pty Ltd. is poised to carve out a niche for itself across a variety of cancers.
PERTH, Australia – After reporting positive data at the American Society of Clinical Oncology (ASCO) meeting for its Akt inhibitor in estrogen receptor (ER)-positive breast cancer, Melbourne-based Prescient Therapeutics Pty Ltd. is poised to carve out a niche for itself across a variety of cancers.
PERTH, Australia – Sydney-based Pharmaxis Ltd. announced a capital raising of A$24 million (US$17.3 million) to ready itself for another partnering play.
PERTH, Australia – Sydney-based Pharmaxis Ltd. announced a capital raising of A$24 million (US$17.3 million) to ready itself for another partnering play. The funds will be raised in a two-tranche placement of 73.4 million ordinary shares priced at A32 cents per share.
PERTH, Australia – Drug development is a risky business, and no one knows that better than U.S. Rep. Chris Collins (R-N.Y.), who likely won't forget how a failed clinical trial at Aussie biotech Innate Immunotherapeutics Ltd. last June ultimately ended his political career. But the thrifty little biotech isn't losing any sleep over Collins. It had already acquired some new assets and was readying them for the clinic when news broke that Collins was indicted for insider trading as a fallout from that failed trial.
PERTH, Australia – Drug development is a risky business, and no one knows that better than U.S. Rep. Chris Collins (R-N.Y.), who likely won't forget how a failed clinical trial at Aussie biotech Innate Immunotherapeutics Ltd. last June ultimately ended his political career. But the thrifty little biotech isn't losing any sleep over Collins. It had already acquired some new assets and was readying them for the clinic when news broke that Collins was indicted for insider trading as a fallout from that failed trial.
PERTH, Australia – New Australian and European guidelines on managing sexually transmitted diseases (STDs) are driving demand for Speedx Ltd.'s molecular diagnostic that simultaneously detects the Mycoplasma genitalium bacteria and the genetic markers linked to antimicrobial resistance.
PERTH, Australia – Melbourne-based Neuren Pharmaceuticals signed a development and commercialization deal with Acadia Pharmaceuticals Inc. worth up to $465 million for North American rights to trofinetide for Rett syndrome and other indications.
